Literature DB >> 17408237

A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Robert J Bauer1, Serge Guzy, Chee Ng.   

Abstract

An overview is provided of the present population analysis methods and an assessment of which software packages are most appropriate for various PK/PD modeling problems. Four PK/PD example problems were solved using the programs NONMEM VI beta version, PDx-MCPEM, S-ADAPT, MONOLIX, and WinBUGS, informally assessed for reasonable accuracy and stability in analyzing these problems. Also, for each program we describe their general interface, ease of use, and abilities. We conclude with discussing which algorithms and software are most suitable for which types of PK/PD problems. NONMEM FO method is accurate and fast with 2-compartment models, if intra-individual and interindividual variances are small. The NONMEM FOCE method is slower than FO, but gives accurate population values regardless of size of intra- and interindividual errors. However, if data are very sparse, the NONMEM FOCE method can lead to inaccurate values, while the Laplace method can provide more accurate results. The exact EM methods (performed using S-ADAPT, PDx-MCPEM, and MONOLIX) have greater stability in analyzing complex PK/PD models, and can provide accurate results with sparse or rich data. MCPEM methods perform more slowly than NONMEM FOCE for simple models, but perform more quickly and stably than NONMEM FOCE for complex models. WinBUGS provides accurate assessments of the population parameters, standard errors and 95% confidence intervals for all examples. Like the MCPEM methods, WinBUGS's efficiency increases relative to NONMEM when solving the complex PK/PD models.

Entities:  

Mesh:

Year:  2007        PMID: 17408237      PMCID: PMC2751305          DOI: 10.1208/aapsj0901007

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  24 in total

1.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

2.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

3.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

4.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

5.  Balanced designs in longitudinal population pharmacokinetic studies.

Authors:  E I Ette; H Sun; T M Ludden
Journal:  J Clin Pharmacol       Date:  1998-05       Impact factor: 3.126

6.  Comparison of population pharmacokinetic modeling methods using simulated data: results from the Population Modeling Workgroup.

Authors:  D J Roe
Journal:  Stat Med       Date:  1997-06-15       Impact factor: 2.373

7.  Hyperparameter estimation using stochastic approximation with application to population pharmacokinetics.

Authors:  F Mentré; A Mallet; J L Steimer
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

8.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

Review 9.  Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.

Authors:  R Gomeni; G Pineau; F Mentré
Journal:  Anticancer Res       Date:  1994 Nov-Dec       Impact factor: 2.480

10.  The estimation of population pharmacokinetic parameters using an EM algorithm.

Authors:  L Aarons
Journal:  Comput Methods Programs Biomed       Date:  1993-09       Impact factor: 5.428

View more
  74 in total

1.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

2.  Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Robert Bauer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-11-19       Impact factor: 2.745

3.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

4.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

5.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

6.  Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics.

Authors:  Cornelia B Landersdorfer; Robert L Findling; Jean A Frazier; Vivian Kafantaris; Carl M J Kirkpatrick
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

7.  The pharmacokinetics of sertraline in overdose and the effect of activated charcoal.

Authors:  Joyce M Cooper; Stephen B Duffull; Ana S Saiao; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

8.  Network pharmacodynamic models for customized cancer therapy.

Authors:  James M Gallo; Marc R Birtwistle
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2015-04-24

9.  VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.

Authors:  Virginie Hervé; Nathalie Rabbe; Laurent Guilleminault; Flora Paul; Laurène Schlick; Nicolas Azzopardi; Michael Duruisseaux; Delphine Fouquenet; Jérôme Montharu; Françoise Redini; Gilles Paintaud; Etienne Lemarié; Jacques Cadranel; Marie Wislez; Nathalie Heuzé-Vourc'h
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Treating children with acute lymphoblastic leukemia and Down syndrome: pharmacokinetics provides insight into vincristine therapy.

Authors:  Clinton F Stewart
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.